Thanks for posting. I went to the 'Conclusions' first up.
"Conclusions
In the DREAM-HF trial, the primary and secondary endpoints were negative. However, MPCs showed positive signals in improving outcomes in prespecified and post hoc exploratory analyses. These hypothesis-generating findings may help identify patients most likely to benefit from MPC therapy."
Pehaps I'm missing something, so can an expert explain the positive aspects of this to a simpleton like me and also for the benefit of mums/dads/newbies.
Also, "Funding Support and Author Disclosures" raises a few questions on impartiality, just sayin'.
Cell Therapy News/Articles, page-17087
-
- There are more pages in this discussion • 966 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 29390 | 93.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 14089 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |